View source for 20240052423. METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF simplified abstract (Pfizer Inc.)

=METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF=


==Organization Name==

[[:Category:Pfizer Inc.|Pfizer Inc.]]


[[Category:Pfizer Inc.]]

==Inventor(s)==

[[:Category:Joshua James Gruber of Dallas CA (US)|Joshua James Gruber of Dallas CA (US)]][[Category:Joshua James Gruber of Dallas CA (US)]]

[[:Category:Melinda Telli of San Francisco CA (US)|Melinda Telli of San Francisco CA (US)]][[Category:Melinda Telli of San Francisco CA (US)]]

==METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240052423 titled 'METHODS OF IDENTIFYING A TUMOR THAT IS SENSITIVE TO TREATMENT WITH TALAZOPARIB AND METHODS OF TREATMENT THEREOF

==Simplified Explanation==

The patent application relates to a method of identifying metastatic tumors with mutations in homologous recombination pathway genes that are sensitive to treatment with talazoparib.

* Determining a homologous recombination deficiency score from a biopsy of the metastatic tumor.
* Administering talazoparib if the homologous recombination deficiency score is at least 33%, and the mutation is not germline BRCA1 or BRCA2.

**Potential Applications:**
- Personalized medicine for cancer treatment.
- Targeted therapy for metastatic tumors with specific mutations.

**Problems Solved:**
- Identifying the most effective treatment for metastatic tumors with mutations in homologous recombination pathway genes.
- Avoiding unnecessary treatments that may not be effective.

**Benefits:**
- Improved treatment outcomes for patients with metastatic tumors.
- Reduced side effects from ineffective treatments.
- Tailored therapy based on individual genetic mutations.


==Original Abstract Submitted==

the present invention relates to a method of identifying a metastatic tumor determined to have a mutation in homologous recombination pathway genes, that is sensitive to treatment with talazoparib, or a pharmaceutically acceptable salt thereof, and methods of treatment thereof, comprising a) determining a homologous recombination deficiency score from a biopsy of the metastatic tumor; and b) administering talazoparib, or a pharmaceutically acceptable salt thereof, if the homologous recombination deficiency score is at least 33%, wherein the mutation is not germline brca1 or germline brca2. the present invention also relates to a method of selecting a subject determined to have a metastatic tumor with a mutation in homologous recombination pathway genes, for treatment with talazoparib, or a pharmaceutically acceptable salt thereof.



[[Category:C12Q1/6886]]